Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
EvaluatePharma
Evaluate Omnium
Japan Drug Forecasts
European Drug Forecasts
Epi Analyzer
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Evaluate Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Pharmasset
December 16, 2016
Hep C settlement pays Merck’s Idenix bill
September 22, 2016
Bubble stocks top the takeover premium charts
September 07, 2016
How Gilead could go back to basics
September 14, 2015
Therapeutic focus – new combos and genotypes the future in hep C
June 30, 2015
Celgene goes for broke
November 27, 2014
Bristol-Myers misses out again in hep C
October 23, 2014
Data in 14 has Regulus joining ranks of hep C high flyers
September 30, 2014
J&J hangs in hep C game with $1.8bn Alios takeout
July 23, 2014
Sovaldi not the first to break the bank
June 09, 2014
Biotech bull market charges with Merck’s Idenix takeout
April 09, 2014
EASL – Cost tops the agenda as hepatitis C enters post-interferon world
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
July 29, 2020
Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020
April 16, 2020
Evaluate Vantage COVID-19 Report
Editor's Picks
November 09, 2020
Pfizer and Biontech snatch first Covid vaccine victory
November 04, 2020
Scanning the horizon for future Covid-19 treatments
November 06, 2020
Ash 2020 preview – early winners and losers
November 05, 2020
Biogen’s aducanumab heads for US approval
October 26, 2020
Balancing the accuracy and cost of antigen testing
